Improved progression-free survival for lutathera over octreotide

Posted by on June 4, 2016 9:21 am
Categories: health

Researchers will present results of the phase 3 NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs).

Leave a Reply

Your email address will not be published. Required fields are marked *